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The present study sought to investigate the genetic variants in drug metabolizing
enzyme and transporter (DMET) genes associated with steady-state plasma
concentrations of risperidone among Thai autism spectrum disorder (ASD) patients.
ASD patients taking risperidone for at least 1 month were enrolled for this
pharmacogenomic study. Genotyping profile was obtained using Affymetrix DMET
Plus array interrogating 1931 variants in 231 genes. Steady-state plasma risperidone
and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass
spectrometry assay. The final analysis included 483 markers for 167 genes. Six
variants, ABCB11 (c.3084A > G, c.∗420A > G, c.∗368G > A, and c.∗236G > A)
and ADH7 (c.690G > A and c.−5360G > A), were found to be associated with
plasma concentrations of risperidone. 9-Hydroxyrisperidone and the total active-moiety
levels were associated with six gene variants, SCLO1B1 (c.−11187G > A and
c.521T > C), SLCO1B3 (c.334G > T, c.699A > G, and c.1557G > A), and SLC7A5
c.∗438C > G. Polymorphisms in UGT2B4 c.∗448A > G and CYP2D6 (c.1661G > C,
c.4180G> C, and c.−2178G> A) showed considerable but not significant associations
with metabolic ratio. This pharmacogenomic study identifies new genetic variants of
DMET genes in monitoring risperidone therapy.
Keywords: risperidone, autism spectrum disorders, pharmacogenomics, drug metabolizing enzymes,
transporters
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INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder typically diagnosed in early childhood, and is
characterized by deficits in social and linguistic communication
skills, along with repetitive and stereotyped behaviors. In
addition, autism patients show symptoms like irritability,
aggressive attitude toward other or property, anxiety, self-
injurious behavior, hyperactivity, and severe temper tantrums
(Ghosh et al., 2013; Bowers et al., 2015). Risperidone, an atypical
antipsychotic, is approved by the Food and Drug Administration
(FDA) to treat disruptive behaviors associated with autism in
children and adolescents(Cohen et al., 2013) demonstrating
antagonism at dopamine D2, serotonin 5HT2A, and adrenergic
α2 receptors (Thyssen et al., 2010).
Plasma concentrations of risperidone and 9-hydroxy-
risperidone vary among individuals, which in turn influences
clinical responses and adverse-effects justifying the regular
need to monitor plasma concentrations of risperidone, 9-
hydroxyrisperidone, and the total active-moiety (Riedel et al.,
2005; Locatelli et al., 2010). Genetic heterogeneity is commonly
regarded as the main cause of this inter-individual variability.
Pharmacogenomics explores the genetic causes of variability in
drug responses, and aids in tailored therapy according to the
individual’s genetic make-up (Collins et al., 2016).
Risperidone undergoes 9-hydroxylation producing 9-hyd-
roxyrisperidone as its active metabolite. CYP2D6 is the key
enzyme for the hydroxylation of risperidone, but CYP3A4
and CYP3A5 enzymes have also been reported to play minor
roles in the metabolism of risperidone (Fang et al., 1999).
9-Hydroxyrisperidone and risperidone, which have similar
pharmacological activities, are collectively termed as the total
active-moiety. Nevertheless, studies have shown that risperidone
and 9-hydroxyrisperidone differ from each other in terms of
regulation of receptor-mediated signaling pathways (Clarke
et al., 2013) and 5-HT2A/D2 affinity ratios with differences in
their therapeutic efficacies or adverse effect profiles (Kozielska
et al., 2012). Risperidone and 9-hydroxyrisperidone are
substrates of P-glycoprotein, an adenosine triphosphate–binding
cassette (ABC) superfamily transporter, and their dispositions
and absorptions might be affected by the functional status
of P-glycoprotein (Nakagami et al., 2005; Corena-McLeod,
2015).
Studies have reported the inter-individual variability in
pharmacokinetic and pharmacodynamics of risperidone leading
to unusual exposures, an occurrence of toxic effects, and
therapeutic failure. Presence of single nucleotide polymorphisms
(SNPs) in the genes encoding phase I and phase II drug-
metabolizing enzymes (DME) alters the activity of enzymes
resulting in four possible phenotypes: poor metabolizer (PM),
intermediate metabolizer (IM), extensive metabolizer (EM), and
ultrarapid metabolizer (UM; Zhou et al., 2009). Drug transporters
are classified as influx solute carrier (SLC) family transporters and
eﬄux ABC family transporters (Yiannakopoulou, 2013). A study
analyzing the associations between drug metabolizing enzyme
and transporter (DMET) polymorphisms and pharmacokinetic
variability of risperidone found associations of polymorphisms
in CYP2D6, TPMT, ADRB1, VKORC1, and COMT with
pharmacokinetic parameters (Cabaleiro et al., 2014). ABCB1
3435C>T genotypes had significant effect on maximum
concentration observed (Cmax) of risperidone and the total
active-moiety, but when ABCB1 3435C>T genotypes were
combined with CYP2D6∗10/∗10 genotype carrying subjects,
significant differences were observed in Cmax, the area under
the curve (AUC) of risperidone, and the total active-moiety as
well (Yoo et al., 2011). Several polymorphisms have been studied
emphasizing the influence of allelic variations among metabolic
enzymes and transporters in the disposition of risperidone
and its phenotypes. An association study of risperidone and 9-
hydroxyrisperidone plasma levels with CYP2D6 polymorphisms
in ASD patients found a significant influence of CYP2D6
variants on plasma risperidone concentrations which provides
evidence of genetic variations of drug exposure and safety
(Vanwong et al., 2016a). Previous studies also reported the
influence of polymorphisms in DMET genes, including CYP2D6,
CYP3A4, CYP3A5, ABCB1, COMT, and VKORC1 on the plasma
concentrations of risperidone, 9-hydroxyrisperidone, and the
total active-moiety (Jovanovic et al., 2010; Xiang et al., 2010;
Suzuki et al., 2012; Cabaleiro et al., 2014). The present authors
previously reported the prevalence of clinically important DMET
SNPs in Thai ASD patients (Medhasi et al., 2016).
The influence of CYP2D6, CYP3A5, and ABCB1 gene
variants on plasma levels of risperidone, 9-hydroxyrisperidone,
and the total active-moiety clearly argues for the need of
pharmacogenetic testing and therapeutic drug monitoring
(TDM) during risperidone therapy (Jovanovic et al., 2010).
The association between genetic variants of DMET genes
and steady-state plasma concentrations of risperidone, 9-
hydroxyrisperidone, total active-moiety, and metabolic ratio
remains unclear. The objective of the present study was to
present the results of the association between genetic variants
of the DMET genes and steady-state plasma concentrations of
risperidone and its metabolite using the Affymetrix DMET Plus
genotyping microarrays.
MATERIALS AND METHODS
Patients
Patients eligible for this study included male and female
adolescents with ASD diagnosed according to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria and being treated with risperidone for at least 4 weeks
prior to blood sample collection. Subjects enrolled were
outpatients from the Yuwaprasart Waithayopathum Child and
Adolescent Psychiatric Hospital, Samut Prakarn, Thailand for
this retrospective pharmacogenomic study. Only patients having
complete data on doses and duration of risperidone were
recruited for this study. Dosing of the risperidone was flexible
depending on response or adverse events. Risperidone dosing
followed the guidelines where the starting dose of risperidone
for the treatment of irritability associated with autistic disorder
is 0.25 mg/day for patients weighing <20 kg and 0.5 mg/day for
patients weighing ≥20 kg, with the target dose of 0.5 mg/day
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(<20 kg) and 1 mg/day (≥20 kg); effective dose range, 0.5–
3 mg/day (Risperdal prescribing information, revised version
2014). Patient compliance was assessed and confirmed by the
nursing staff.
Medications co-administered along with risperidone
were recorded. In the case of the co-occurring attention
deficit/hyperactivity disorder, stimulants were allowed to
continue, provided no changes were made during the study.
The exclusion criteria included patients with severe physical
disabilities and currently being treated with other antipsychotics
that could interfere with the pharmacokinetics of risperidone.
This study was carried out in accordance with the principles
of the Declaration of Helsinki, and was approved by the
Ramathibodi Ethics Committee (Bangkok, Thailand). The
parents of all patients included in the study received an
explanation of the purpose and experimental procedures of the
study. A written informed consent was obtained from the parents
or guardians of the patients before the study.
Blood Sampling and Measurements of
Risperidone and 9-Hydroxyrisperidone
Blood samples were drawn from the patients during 08:00–09:00
AM prior to the next dose of risperidone intake to determine the
steady-state plasma trough concentrations (Css) of risperidone
and 9-hydroxyrisperidone. Plasma samples were collected into
EDTA tubes and stored at−80◦C until analyzed at the laboratory
for TDM in the Faculty of Medicine, Ramathibodi Hospital
(Bangkok, Thailand).
The quantitative determinations of Css of risperidone
and 9-hydroxyrisperidone were performed using a modified
validated liquid chromatography coupled with the tandem mass
spectrometry (LC-MS/MS) method (Vanwong et al., 2016b).
The instrument consisted of an Agilent 1260 HPLC system
(Agilent Technologies, Santa Clara, CA, USA) coupled to an
API 3200TM (SCIEX) mass spectrometer. The mass-to-charge
ratio (m/z) applied for ion monitoring was 411→191 for
risperidone, 428→207 for 9-hydroxyrisperidone, and 328→270
for the internal standard clozapine.
The values of intra-assay and inter-assay coefficients of
variation were less than 9% for risperidone and less than 6%
for 9-hydroxyrisperidone. The average accuracy was 98–110%
for risperidone and 95–105% for 9-hydroxyrisperidone. The
lower limit of quantifications (LLOQ) was 0.2 and 0.5 ng/ml for
risperidone and 9-hydroxyrisperidone.
DMET Plus Array and SNP Genotyping
and Quality Control
Genomic DNA was extracted from EDTA-whole blood using
the MagNA Pure Compact System (Hoffman-La Roche Ltd.,
Basel, Switzerland). Genotyping of SNPs was performed using
molecular inversion probes (MIP) technology on the Affymetrix
DMETTM Plus GeneChip microarray platforms (Affymetrix
Inc., Santa Clara, CA, USA). The Affymetrix DMETTM Plus
microarray enables the genotyping of 1,936 genetic markers
(1,931 SNPs and 5 CNVs) across 231 genes having functional
significance in drug pharmacokinetics (Bonifaz-Pena et al., 2014).
The PCR product from MIP technology undergoes enzymatic
fragmentation and then hybridization to the DMET microarray
for SNP discrimination and genotyping (Hardenbol et al., 2003;
Burmester et al., 2010). Washing and staining of DMET arrays
were performed using Affymetrix fluidic stations and scanned
by the Affymetrix GeneChip R© Scanner 3000 (Affymetrix Inc,
Santa Clara, CA, USA). The genotyping profiles of DMET
SNPs were generated with Affymetrix DMET Console software R©
(version 1.3).
Genotyping of the previously associated CYP2D6 variants,
1846G > A, rs3892097; 100C > T, rs1065852; and 2988G > A,
rs28371725, with risperidone pharmacokinetics (Scordo et al.,
1999; Yasui-Furukori et al., 2003; Riedel et al., 2005; Vanwong
et al., 2016a) which failed the quality control (QC) in microarray
analyses were identified using the PCR-based TaqMan allele
discrimination method (Applied Biosystems, Carlsbad, CA,
USA) for further analysis.
The QC check on the genotyping data was performed using
the R package “GenABEL” and Haploview software (Barrett
et al., 2005). Individuals with a <90% genotyping call rate were
excluded and SNPs with more than 5% missing genotypes were
excluded. Also, SNPs with minor allele frequency (MAF) < 0.05,
a deviation from Hardy–Weinberg equilibrium (HWE) at
P > 0.001, and variants of chromosome X were discarded from
further analysis.
Data Analyses and Statistics
The null hypothesis for this genetic association study was that
genetic variants of DMET genes are not associated with Css
of risperidone and 9-hydroxyrisperidone. Results are expressed
as median and the range, unless specified otherwise. The
Shapiro–Wilk test was used to assess the normality of the plasma
concentrations of risperidone and 9-hydroxyrisperidone. Q-Q
plots, multidimensional scaling (MDS) plot, and association
analysis of DMET markers with plasma concentrations of
risperidone, 9-hydroxyrisperidone, the total active-moiety, and
metabolic ratio were estimated using Cochran–Armitage test for
trends in the GenABEL package of R version 3.1.2 (Aulchenko
et al., 2007). The P-value adjusted after Bonferroni correction was
set at 2.5 × 10−5. Being an exploratory study, however, genetic
markers were selected as notable ones in the association analysis
with a P-value less than 0.01, corrected for possible inflation due
to some degree of stratification. The demographic, phenotypic
measurements and linear regression analyses were calculated
using the SPSS (version 17.0). P< 0.05 was considered significant
in the linear regression analysis. Pairwise linkage disequilibrium
analysis was performed using Haploview 4.2.
RESULTS
Characteristics of the Study Cohort and
Selection of DMET Markers
After screening the 104 individuals for missing data, 103 patients
passed the genotyping call rate threshold set at 90%. In addition,
one patient was excluded because of being too highly identical
by descent (IBS) (≥0.95). Table 1 shows the demographic
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TABLE 1 | Demographic and clinical characteristics of the ASD patients.
Characteristic n = 102
Age, years (range) 8.8 (3.4–18.6)
Sex:
Male
Female
87 (85.3%)
15 (14.7%)
Risperidone treatment
Risperidone dose, mg/day (range) 0.5 (0.2–4)
Risperidone duration, months (range) 41.62 (1.03–152.97)
Risperidone single medication, n (%) 63 (61.76)
Concomitant treatments, n (%)
Methylphenidate
Valproic acid
Methylphenidate + valproic acid
Methylphenidate + fluoxetine
Pyrithioxine
Sertraline
17 (16.67)
16 (15.69)
3 (2.94)
1 (0.98)
1 (0.98)
1 (0.98)
Median of plasma drug concentrations, ng/ml (IQR)
Risperidone 0.83 (2.22)
9-hydroxyrisperidone 6.75 (7.42)
Total active-moiety 8.48 (8.34)
Median metabolic ratio (IQR) 0.08 (0.31)
ASD, autism spectrum disorder; IQR, interquartile range.
and clinical characteristics of the 102 autistic patients treated
with risperidone. The study population had a median (range)
age of 8.8 (3.4–18.6) years which was predominantly boys
(85.3%). The median risperidone dose was 0.5 (range:
0.2–4) mg/day. Patients had a median range of risperidone
duration of treatment of 41.62 (1.03–152.97) months. The
percentage of the patients treated with only risperidone was
61.76%. Concomitant medication use among the patients was
16.67% prevalently using methylphenidate followed by 15.69%
patients who were using valproic acid. Other concomitant
medicines included fluoxetine, pyrithioxine, and sertraline.
After filtering 1931 SNP markers with the QC parameters, 171
(8.9%) markers were removed owing to an overall genotyping
call rate of less than 95%. From the remaining 1760 markers,
1229 markers were removed from further analysis because their
MAF was less than 5%. Furthermore, 46 markers on the X
chromosome and two markers with HWE P-value < 0.001 were
excluded as well. As a result, 483 (25%) markers of 1931 markers
were included for final analysis. A MDS plot did not show any
clear clusters which means that no population stratification exists
and also there were no differences in allele frequencies between
populations (Supplementary Figure S1).
Plasma Concentrations of Risperidone
and Its Metabolite
The median (IQR) trough levels of risperidone and 9-
hydroxyrisperidone measured 12 h after the last risperidone
administration were 0.83 (2.22) ng/ml and 6.75 (7.42) ng/ml. The
median (IQR) plasma concentration of the total active moiety
was 8.48 (8.34) ng/ml as shown in Table 1. The median (IQR)
metabolic ratio was 0.08 (0.31).
Association of DMET SNPs in
Steady-State Plasma Concentrations of
Risperidone and 9-Hydroxyrisperidone
The DMET SNPs showing significant associations with plasma
concentrations of risperidone and its metabolite with a minimum
P-value less than 0.01 included 22 SNPs of seven genes from the
GeneChip microarray analyses; Tables 2–5. The SNPs showing
a suggestive evidence of association, at P < 0.05, are shown in
Supplementary Tables S1–S4.
The top significant findings of DMET SNPs associated with
steady-state plasma concentrations of risperidone are shown
in Table 2 and Figure 1A. Of all the DMET SNPs, six SNPs
were found to be associated with plasma concentrations of
risperidone (P < 0.01). Analysis showed 4 ABCB11 SNPs,
including c.3084A > G (rs497692), c.∗420A > G (rs496550),
c.∗368G > A (rs495714), and c.∗236G > A (rs473351), and
2 ADH7 SNPs which included c.690G > A (rs971074) and
c.−5360G > A (rs1442477) that had significant associations.
The 9-hydroxyrisperidone plasma concentrations correlated
significantly with the DMET genetic markers (P < 0.01) and
are illustrated in Table 3 and Figure 1B. A total of six genetic
variations among the SLC transporter family were associated
with the plasma concentrations of 9-hydroxyrisperidone. Of
the SLCO1B1 polymorphisms, c.−11187G > A (rs4149015) and
c.521T > C (rs4149016) had significant associations (P < 0.01).
Three variants of SLCO1B3, including c.334G > T (rs4149117),
c.699A > G (rs7311358), and c.1557G > A (rs2053098) that
influenced the plasma concentrations of 9-hydroxyrisperidone.
SLC7A5 c.∗438C > G (rs1060253) also showed considerable
influence in the plasma concentrations of the metabolite.
As Table 4 and Figure 1C shows, identical DMET SNPs were
associated with plasma concentrations of the total active-moiety
as were identified for the associations with 9-hydroxyrisperidone.
The DMET SNPs significantly influenced the metabolic ratio
(P < 0.01, Table 5; Figure 1D) that involved four metabolic
enzyme variants. UGT2B4 c.∗448A > G (rs1131878), CYP2D6
c.1661G > C (rs1058164), CYP2D6 c.4180G > C (rs1135840),
and CYP2D6 c.-2178G>A (rs28360521) were the four metabolic
enzyme polymorphisms highly associated with metabolic ratio.
Association of CYP2D6 SNPs in
Steady-State Plasma Concentrations of
Risperidone and 9-Hydroxyrisperidone
Using TaqMan Assay
The relationships between the CYP2D6 variants (rs3892097,
rs1065852, and rs28371725) and the plasma concentrations
of risperidone, 9-hydroxyrisperidone, the total active-moiety,
and the metabolic ratio are shown in Table 6. A significant
influence in the plasma concentration of risperidone (P = 0.009)
was observed with CYP2D6 c.2988G > A (rs28371725),
but no significance was found in the plasma concentration
of 9-hydroxyrisperidone, the total active-moiety, and
metabolic ratio. There was significant influence of CYP2D6
c.100C > T (rs1065852) in the metabolic ratio (P = 0.004),
whereas no influence was found for plasma concentrations
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TABLE 2 | Top SNPs associated with steady-state plasma risperidone concentrations (Sample size = 102).
SNP rsID Marker name Amino acid change Chromosome Cytoband P-values
rs497692 ABCB11 c.3084A > G A1028A 2 q24.3 0.0062
rs496550 ABCB11 c.∗420A > G 3′UTR 2 q24.3 0.0063
rs495714 ABCB11 c.∗368G > A 3′UTR 2 q24.3 0.0068
rs971074 ADH7 c.690G > A R230R 4 q23 0.0092
rs1442477 ADH7 c.−5360G > A Promoter 4 q23 0.0092
rs473351 ABCB11 c.∗236G > A 3′UTR 2 q24.3 0.0094
SNPs, single-nucleotide polymorphisms; UTR, untranslated region.
TABLE 3 | Top SNPs associated with steady-state plasma 9-hydroxyrisperidone concentrations (Sample size = 102).
SNP rsID Marker name Amino acid change Chromosome Cytoband P-values
rs4149015 SLCO1B1 c.−11187G > A Promoter 12 p12.2 0.0001
rs1060253 SLC7A5 c.∗438C > G 3′UTR 16 q24.2 0.0005
rs4149117 SLCO1B3 c.334G > T A112S 12 p12.2 0.0021
rs7311358 SLCO1B3 c.699A > G I233M 12 p12.2 0.0021
rs2053098 SLCO1B3 c.1557G > A A519A 12 p12.2 0.0021
rs4149056 SLCO1B1 c.521T > C V174A 12 p12.1 0.0090
TABLE 4 | Top SNPs associated with steady-state plasma total active-moiety concentrations (Sample size = 102).
SNP rsID Marker name Amino acid change Chromosome Cytoband P-values
rs4149015 SLCO1B1 c.−11187G > A Promoter 12 p12.2 0.0001
rs1060253 SLC7A5 c.∗438C > G 3′UTR 16 q24.2 0.0007
rs4149117 SLCO1B3 c.334G > T A112S 12 p12.2 0.0015
rs7311358 SLCO1B3 c.699A > G I233M 12 p12.2 0.0015
rs2053098 SLCO1B3 c.1557G > A A519A 12 p12.2 0.0015
rs4149056 SLCO1B1 c.521T > C V174A 12 p12.1 0.0081
TABLE 5 | Top SNPs associated with risperidone/9-hydroxyrisperidone metabolic ratio (Sample size = 102).
SNP rsID Marker name Amino acid change Chromosome Cytoband P-values
rs1131878 UGT2B4 c.∗448A > G 3′UTR 4 q13.2 0.0022
rs1058164 CYP2D6 c.1661G > C V136V 22 q13.2 0.0030
rs1135840 CYP2D6 c.4180G > C S486T 22 q13.2 0.0046
rs28360521 CYP2D6 c.−2178G > A 5′UTR 22 q13.2 0.0050
of risperidone, 9-hydroxyrisperidone, and the total active-
moiety. CYP2D6 c.1846G > A (rs3892097) did not show any
associations with the plasma concentrations of risperidone,
9-hydroxyrisperidone, the total-active-moiety, and the metabolic
ratio.
Linkage Disequilibrium Analysis
Linkage disequilibrium analysis of 14 SNPs across five genes is
shown in Figure 2. Strong linkage disequilibria (D′-values> 0.9)
were observed between SLCO1B3 rs4149117, rs7311358, and
rs2053098; CYP2D6 rs1058164, rs1135840, and rs28360521;
ADH7 rs971074 and rs1442477; and ABCB11 rs496550, rs497692,
rs495714, and rs473351. Linkage disequilibrium was not strong
across the SLCO1B1 rs4149015 and rs4149056.
DISCUSSION
In this study, the associations of DMET genetic markers
with steady-state plasma concentrations of risperidone and
9-hydroxyrisperidone among Thai ASD risperidone-treated
patients using Affymetrix DMET Plus microarray platform
were evaluated. The major findings from this exploratory
pharmacogenomic investigation were the abilities of the
genetic markers involved in drug metabolism and transport
to predict inter-individual variability in steady-state plasma
concentrations of risperidone and its active metabolite,
9-hydroxyrisperidone. It showed that six polymorphisms
(4 ABCB11 variants and 2 ADH7 variants) were strongly
associated with plasma concentrations of risperidone; six SLC
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FIGURE 1 | Manhattan plots of associations of plasma concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety, and metabolic ratio
with 483 drug metabolizing enzyme and transporter (DMET) single nucleotide polymorphisms (SNPs). The horizontal x-axis represents the chromosomal
positions; the vertical y-axis represents –log10P-values from the linear regression. The red horizontal line represents the significance level of P = 2.5 × 10−5 after
Bonferroni correction. The horizontal blue line represents the P-value of 0.01. (A) Manhattan plot showing the significance of DMET SNPs with plasma concentrations
of risperidone. (B) Manhattan plot showing the significance of DMET SNPs with plasma concentrations of 9-hydroxyrisperidone. (C) Manhattan plot showing the
significance of DMET SNPs with plasma concentrations of total-active moiety. (D) Manhattan plot showing the significance of DMET SNPs with metabolic ratio.
polymorphisms (3 SLCO1B3 variants, 2 SLCO1B1 variants,
and 1 SLC7A5 variant) were strongly associated with plasma
concentrations of 9-hydroxyrisperidone and the total active-
moiety; and four polymorphisms (3 CYP2D6 variants and
1 UGT2B4 variant) were strongly associated with metabolic
ratio.
With the increased recognition of the role of transporters
in drug disposition with pharmacologically important allelic
variability, both ABC and SLC transporters have been the scope
of analysis in the present study. These results showed that
rs497692, rs496550, rs495714, and rs473351 in ABCB11 were
associated with plasma concentrations of risperidone. ABCB11 is
a member of the ABC transporter group, subfamily B, member
11, and is also known as sPgp (sister of P-glycoprotein)1.
Although ABCB11 has been studied extensively in other
conditions, the report herein found new SNPs of ABCB11
1http://www.ncbi.nlm.nih.gov/gene/8647
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TABLE 6 | Relationship between CYP2D6 variant alleles and the plasma
concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety,
and metabolic ratio (Sample size = 102).
CYP2D6
marker
P-values
Risperidone 9-
hydroxy-
risperidone
Total
active-
moieties
Risperidone/
9-hydroxy-
risperidone
c.1846G > A,
rs3892097
0.39 0.9 0.22 0.37
c.100C > T,
rs1065852
0.12 0.14 0.25 0.004∗
c.2988G > A,
rs28371725
0.009∗ 0.9 0.74 0.26
∗P-value was considered significant.
that are associated with plasma concentrations of risperidone.
In the study, genes and SNPs that do not have direct
interactions with risperidone and its metabolite have been
discovered and showed associations with plasma concentrations
of risperidone and its metabolite. SNPs related to ADH7
(rs971074 and rs1442477) showed an association with plasma
concentrations of risperidone. ADH7 is a class IV alcohol
dehydrogenase which metabolizes ethanol to acetaldehyde
(Jairam and Edenberg, 2014). It can then be concluded that there
is a possible role for multiple genetic variants which previously
lacked evidence of pharmacogenomic associations and known
biological pathways and that now lead to phenotypic outcomes
similar to the established ones. This explains the advantage
of microarray technology where an a priori assumption is
avoided and an established physiological network among several
genes in the body is recognized (Nigam, 2015; Arbitrio
et al., 2016). The mechanistic functional effects of previously
unrelated genes, however, should be further investigated in
an independent sample set to reveal the linking molecular
pathways.
Other top SNPs associated with plasma concentrations of
9-hydroxyrisperidone and the total active-moiety were SLC
transporter variants. A previous study reported the influence
of SLC6A4 in sexual dysfunction and weight gain among
risperidone treated patients (Almoguera et al., 2013). The
present study, however, found SNPs among SLCO1B1, SLCO1B3,
and SLC7A5 were associated with plasma concentrations of
9-hydroxyrisperidone and the total active-moiety. CYP2D6
polymorphisms influenced the plasma risperidone to
9-hydroxyrisperidone ratio in this study which suggests the
functional role of CYP2D6 on a genetic basis. Among the Phase
II enzymes, SNP rs1131878 in UGT2B4 was shown to affect
the risperidone metabolic ratio. UDP-glucuronyltransferase
(UGT) enzymes catalyze the glucuronidation reactions and
are an important aspect for variability in pharmacokinetics
and clinical responses of antipsychotic agents (Kiang et al.,
2005).
This pharmacogenomic study identifies newer variants of
DMET gene polymorphisms with greater susceptibility to alter
plasma concentrations of risperidone, 9-hydroxyrisperidone,
total active-moiety, and metabolic ratio. Notably, this
study did not find any significant associations among the
variants previously reported to influence risperidone and 9-
hydroxyrisperidone plasma concentrations. Polymorphisms
among the main metabolic polymorphic enzyme CYP2D6 and
the major transporter protein ABCB1 did not correlate with the
plasma concentrations of risperidone or 9-hydroxyrisperidone
as has been reported in earlier studies among the schizophrenic
patients (Roh et al., 2001; Jovanovic et al., 2010). This finding
implicates the limited importance of CYP2D6 and ABCB1
polymorphisms for the plasma concentrations of risperidone
and 9-hydroxyrisperidone. ABCB1 3435C > T polymorphisms,
however, were significantly associated with pharmacokinetic
parameters (Cmax, AUC, and MR) of risperidone among
individuals who were carriers of CYP2D6∗10/∗10 (Yoo et al.,
2011). The reduced function variant CYP2D6∗10 which is
highly prevalent among Asian populations and associated
with plasma concentrations of risperidone (Roh et al., 2001;
Vanwong et al., 2016a) failed to pass the QC in the microarray
assay. To make these results more conclusive, CYP2D6
variants (rs3892097, rs1065852, and rs28371725) that showed
significant influence in pharmacokinetics of risperidone in
previous studies were genotyped using the TaqMan assay.
The assay found the involvement of CYP2D6 variant alleles
in the metabolism of risperidone. The presence of a strong
relationship between CYP2D6 variants and metabolism of
risperidone in both microarray and TaqMan assays suggests
the important role of CYP2D6 genotyping during risperidone
treatment.
A cautious approach for the implementation of the
information from this study is recommended as many SNPs
did not pass the QC step and these SNPs could not be analyzed
for associations with plasma concentrations of risperidone and
9-hydroxyrisperidone. A majority of the SNPs were discarded
due to the QC filtering criteria of MAF < 0.05. It is likely that
rare variants affecting the plasma concentration of risperidone
and 9-hydroxyrisperidone might have been missed. Due to
the lack of sample size, only the SNPs with a MAF > 0.05
were included and the possibility of false-positive findings was
avoided.
The median risperidone dose was relatively lower (0.5 mg/day)
along with plasma levels of the total active-moiety (8.48 ng/ml)
which are lower than the values reported earlier causing
extrapyramidal side effects (EPS; Spina et al., 2001). Linear
regression analysis showed a significant influence of the
risperidone dose in the plasma concentration of risperidone, 9-
hydroxyrisperidone, and the total active-moiety but no effect
on the metabolic ratio. The duration of risperidone therapy did
not affect the plasma levels of risperidone, 9-hydroxyrisperidone,
active-moiety, and metabolic ratio. Age affected the plasma level
of 9-hydroxyrisperidone, the total active-moiety, and metabolic
ratio. These findings suggest the possible variables responsible
for interindividual variations in plasma concentrations of
risperidone and its metabolite. Similar findings were reported
in an earlier study with a similar effect of age on the plasma
concentrations of the total active-moiety (Aichhorn et al.,
2005).
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FIGURE 2 | Haploview linkage disequilibrium map of SNPs across DMET genes: (A) SLCO1B3; (B) CYP2D6; (C) ADH7; (D) ABCB11; and (E) SLCO1B1.
Pairwise linkage disequilibrium (D′) values are given in blocks for each SNP combination. Dark red shading denotes D′-values > 0.9, and empty dark red blocks
indicate D′values of 1.0.
This study has limitations. The lack of validation of the
most significant (P < 0.01) DMET variants and association of
steady-state plasma concentrations with drug response limits
the significance of the study. These results should be verified
and clinically interpreted in an independent cohort to avoid
the risk of false-positive findings. Also, none of the variants
met Bonferroni cutoff value. The exploratory nature of this
study, however, suggests the preliminary results to be taken
into consideration for further correlation studies. Another
limitation is the absence of genomic control which could have
false-negative conclusions. The lack of independent validation
creates a space for other causative factors, such as age,
dosage, and environmental interactions to be implicated for
the influence on plasma concentrations of risperidone and its
metabolite.
Despite limitations, therapeutic implications from
these findings may aid in avoiding toxic plasma levels of
risperidone and its metabolite in long term treatment. This
pharmacogenomic study provides a mechanistic understanding
for individual differences in pharmacokinetics of drugs and may
have an outstanding application in the improved personalized
treatment of autistic patients in risperidone dosing, efficacy, and
side effects. This study opens up the prospect for association of
DMET genetic variants with treatment response and adverse
effects in future studies. All the patients involved in this study
were unrelated which potentially avoided the bias of genotype
within families being over-represented.
In summary, this study provides a pharmacogenomic
approach to further investigate the DMET genetic variants
which influence plasma concentrations of risperidone and its
metabolite. The treatment of ASD should be based on genetic
factors making the challenge of psychopharmacological
treatment more efficacious with fewer adverse events.
A caution must be exercised, however, in transferring
the pharmacogenomic data into clinical settings unless the
genotype-phenotype link is clearly validated.
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